DrugPatentWatch Database Preview
Details for Patent: 8,877,708
Which drugs does patent 8,877,708 protect, and when does it expire?
Patent 8,877,708 protects CYCLOSET and is included in one NDA.
This patent has eight patent family members in six countries.
This patent has eight patent family members in six countries.
Summary for Patent: 8,877,708
| Title: | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
| Abstract: | The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge. |
| Inventor(s): | Cincotta; Anthony H. (Tiverton, RI) |
| Assignee: | VeroScience, LLC (Tiverton, RI) |
| Application Number: | 13/375,810 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,877,708
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veroscience | CYCLOSET | bromocriptine mesylate | TABLET;ORAL | 020866-001 | May 5, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 8,877,708
| PCT Information | |||
| PCT Filed | June 07, 2010 | PCT Application Number: | PCT/US2010/037605 |
| PCT Publication Date: | December 09, 2010 | PCT Publication Number: | WO2010/141938 |
Non-Orange Book US Patents Family Members for Patent 8,877,708
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,352,025 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders | ➤ Sign Up |
| 9,895,422 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,877,708
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Japan | 2016026168 | ➤ Sign Up | |||
| Japan | 5883382 | ➤ Sign Up | |||
| Japan | 2012529434 | ➤ Sign Up | |||
| European Patent Office | 2437732 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
